The laboratory is active in the development of:

New electronic ECG waveform monitoring devices
State-of-the-art technology applications to capture cardiac safety and efficacy measures in multicenter global clinical trials
In ST segment elevation myocardial infarction (STEMI) and acute coronary syndromes, quantitative ST-segment analyses performed in more than 10 million ECGs have measured therapeutic benefit of drugs and devices in many trials, making ST-segment monitoring the most well established biomarker of cardiac efficacy.